Indian Pharma

Sun Pharma's Organon deal lifts stock, but growth concerns and high debt at the acquired firm may cap upside despite synergy potential

Pharma veteran Umang Vohra to lead Advent-backed Cohance Lifesciences as chairman and CEO, succeeding Vivek Sharma amid efforts to revive growth and address regulatory challenges

Currently, more than 95 per cent of Rubicon's revenue comes from the United States (US), where the company has built a generics and specialty portfolio

Nearly six decades after its founding, Lupin is targeting its next global growth phase in the US with a strategy centred on complex generics, biosimilars and innovation

India and Uzbekistan have launched a policy-backed pharma-nutraceutical corridor to improve regulatory alignment, investment and market access for manufacturers targeting the $7-10 billion Eurasian he

The Indian pharmaceutical market posted 11% growth in February 2026, driven by strong therapy performance, while Mounjaro remained India's highest-selling drug by value for a fifth month

Novartis exits India's mass-market generics, signalling a deeper split between MNC innovation bets and domestic pharma scale

Lupin management remains confident that the India formulations business will continue to outperform IPM by 1.2-1.3 times, supported by strong sales force and pipeline of new product launches.

At the IPA summit, pharma leaders said India's 2047 ambitions depend on embedding AI, strengthening trust and accelerating innovation, as speed and quality become the sector's defining advantages

USFDA data show OAI rates for Indian pharma plants falling to 8% by 2025 even as global outcomes worsen, reflecting stronger quality systems, technology adoption and compliance culture

Ind-Ra says Indian drugmakers will still see 10% revenue growth in FY27 driven by domestic demand and CDMO traction, despite weaker US sales after Revlimid expiry

Industry executives say the US-Bangladesh reciprocal trade agreement is unlikely to materially affect India's pharma and medtech exports, given India's scale and established FDA-approved supply chains

The Indian Pharmacopoeia Commission (IPC) has signed memoranda of understanding with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services Limited, to strengthen drug safety, quality assurance, and capacity-building initiatives. The IPC, an autonomous body under the Health Ministry, has been making efforts to foster institutional partnerships with regulatory bodies, professional councils, quality organisations, and public sector enterprises to strengthen pharmacovigilance systems, enhance professional competencies, and promote uniform standards for medicine quality and patient safety across India. The memorandum of understanding (MoU) signed between IPC and Goa State Pharmacy Council (GSPC) provides a structured framework for collaboration in pharmacovigilance, rational use of medicines, and professional development of pharmacists in the state, the health ministry said in a statement. It envisages promotion of the National Formulary of India among ...

Dr Reddy's, Biocon and Sun Pharma are exploring human-based testing methods that could halve drug development timelines and sharply reduce costs, while meeting global regulatory standards

Finance Minister Nirmala Sitharaman announced Mission Biopharma Shakti in the Budget, a five-year ₹10,000 crore programme to build domestic capabilities in biologics, biosimilars and clinical research

EU's zero-tariff offer on most chemical and medical exports is set to boost India's pharma, medtech and biosimilars access to European markets

Stricter rules to curb antimicrobial resistance may limit antibiotic sales growth in 2026, as India tightens OTC use and pushes prescription-led, responsible consumption

In H1FY26, total revenue of the Sai Life Sciences increased by 53% YoY at ₹1,034 crore, driven by healthy growth across both the CRO and the CDMO business.

Patent expiries of blockbuster weight-loss drug semaglutide may create a ₹5,000 crore generic opportunity for Indian pharma firms across India and key emerging and regulated markets

OAI cases nearly halve in 2025, overall inspection volumes also fell 25%